Can fibromyalgia be considered a characteristic symptom of climacterium?

2021 ◽  
pp. postgradmedj-2021-140336
Author(s):  
Ipek Betul Ozcivit ◽  
Cemal Tamer Erel ◽  
Fatih Durmusoglu
Keyword(s):  
Sleep Disturbances ◽  
Neuroprotective Effect ◽  
Hormone Replacement ◽  
Gastrointestinal Symptoms ◽  
Pain Syndrome ◽  
Climacteric Syndrome ◽  
Mood Changes ◽  
Characteristic Symptom ◽  
Triggering Factor ◽  
Brain Neurotransmitter

Fibromyalgia syndrome (FMS) is a chronic pain syndrome, characterised by diffuse pain in musculoskeletal system and accompanied by stiffness, fatigue, tender points, sleep disturbances and cognitive and gastrointestinal symptoms. It affects middle-aged women (between 40 and 65) predominantly. Climacteric syndrome, which is characterised by vasomotor, somatic (headache, sleep disorders, myalgia and arthralgia) and psychical (mood changes) symptoms, results from the change in brain neurotransmitter concentrations due to gradual decline of ovarian hormone levels. Currently, studies focus on the similarities of FMS and climacteric syndrome in terms of age of occurrence, epidemiology, etiopathogenesis, symptomatology and treatment. Hormonal fluctuation during menopausal transition is likely the triggering factor for both syndromes. Therefore, hormone replacement therapy is a favourable approach in the treatment of FMS due to the antiallodynic, anti-inflammatory and neuroprotective effect of oestrogen. In this review, we emphasise the similarity of FMS and climacteric syndrome and suggested that FMS could be considered as a characteristic symptom of climacterium.

Cognitive disorders in perimenopausal women

2021 ◽  
pp. 47-49
Author(s):  
L. V. Tkachenko ◽  
O. V. Kurushina ◽  
Yu. S. Vorobyova
Keyword(s):  
Hormone Replacement Therapy ◽  
Neurodegenerative Diseases ◽  
Replacement Therapy ◽  
Steroid Hormones ◽  
Neuroprotective Effect ◽  
Hormone Replacement ◽  
Hot Flashes ◽  
Cognitive Disorders ◽  
Mood Changes ◽  
Perimenopausal Women

The article is devoted to the discussion of possible mechanisms of the development of cognitive disorders, the onset and progression of neurodegenerative diseases and the level of sex hormones in women during perimenopause, a condition associated with endocrine changes caused by a decrease in the follicular mass of the ovaries, and, as a consequence, a decrease in the level of their steroid hormones (in particular, estrogen). It is known that estrogen has a neuroprotective effect, affects the mental and cognitive spheres. Reducing it in the perimenopausal period contributes to the appearance of vegetative symptoms (hot flashes, insomnia, mood changes, etc.), increases the risk of developing depressive-anxiety symptoms, cognitive disorders. In order to correct them and prevent the development of neurodegenerative diseases, it is possible to use hormone replacement therapy to prolong the neuroprotective effect of estrogens in a woman’s body.

President John F Kennedy’s medical history: coeliac disease and autoimmune polyglandular syndrome type 2

2020 ◽  
Vol 96 (1139) ◽  
pp. 543-549
Author(s):  
Donatella Macchia ◽  
Donatella Lippi ◽  
Raffaella Bianucci ◽  
Simon Donell
Keyword(s):  
Coeliac Disease ◽  
Medical History ◽  
Gastrointestinal Symptoms ◽  
Pain Syndrome ◽  
Syndrome Type ◽  
Autoimmune Polyglandular Syndrome ◽  
History Of ◽  
Autoimmune Polyglandular Syndrome Type ◽  
Back Problem

President John F. Kennedy (JFK) had a complex medical history that is now thought to be an autoimmune polyglandular syndrome type 2 with Addison’s disease and hypothyroidism. He also had gastrointestinal symptoms from adolescence, which now fit well with coeliac disease. In addition, he had a chronic back problem, which contributed to a chronic pain syndrome. This review looks at JFK’s various diseases and focusses on the history of coeliac disease, as well as its presentation. JFK’s Irish ancestry supports the hypothesis of a coeliac disease started early in his youth.

Negative mood changes during hormone replacement therapy: A comparison between two progestogens

2000 ◽  
Vol 183 (6) ◽  
pp. 1419-1426 ◽  
Author(s):  
Inger Björn ◽  
Marie Bixo ◽  
Karin Strandberg Nöjd ◽  
Sigrid Nyberg ◽  
Torbjörn Bäckström
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Negative Mood ◽  
Mood Changes

scholarly journals Quality of Life in Arthritis Patients Using Nonsteroidal Anti-Inflammatory Drugs

1999 ◽  
Vol 13 (2) ◽  
pp. 129-133 ◽  
Author(s):  
Ingela Wiklund
Keyword(s):  
Quality Of Life ◽  
Sleep Disturbances ◽  
Gastrointestinal Symptoms ◽  
Health Related Quality ◽  
Nsaid Treatment ◽  
Gastrointestinal Problems ◽  
Related Quality ◽  
Health Related ◽  
Anti Inflammatory

Arthritis is a painful and disabling condition. To suppress the pain and the inflammatory process, patients are often chronic nonsteroidal anti-inflammatory drug (NSAID) users. Chronic use of NSAIDs may induce peptic ulcer, dyspeptic problems and heartburn. Therefore, these patients are often provided with treatment to relieve and/or protect against gastrointestinal problems. Rheumatic disorders also affect a range of health-related quality of life domains. In one study, patients with NSAID-associated gastroduodenal lesions complained about lack of energy, sleep disturbances, emotional distress and social isolation in addition to pain and mobility limitations. The degree of distress and dysfunction differed markedly from scores in an unselected population. Clinical trial data suggest that acid-suppressing therapy with omeprazole is superior to therapy with misoprostol and ranitidine in healing gastroduodenal lesions and preventing abdominal pain, heartburn and indigestion symptoms during continued NSAID treatment. Because arthritic patients are severely incapacitated by their condition regarding most aspects of health-related quality of life, it is important to offer a treatment that is effective in healing and preventing NSAID-induced ulcers and gastrointestinal symptoms during continued NSAID treatment without further compromising the patients’ quality of life. Treatment with omeprazole once daily has been shown to be superior to that with ranitidine and misoprostol in this respect.

Did ‘the Princess on the Pea— Suffer from Fibromyalgia Syndrome?

2007 ◽  
Vol 25 (4) ◽  
pp. 184-197 ◽  
Author(s):  
Thomas Lundeberg ◽  
Iréne Lund
Keyword(s):  
Cognitive Dysfunction ◽  
Sleep Disturbances ◽  
Fibromyalgia Syndrome ◽  
Short Term Memory ◽  
Treatment Strategies ◽  
Specific Effect ◽  
Pain Syndrome ◽  
Individual Variability ◽  
Specific Effects ◽  
Systematic Effects

Fibromyalgia syndrome (FMS) is a chronic pain syndrome characterised by central sensitisation resulting in hypersentivity of the skin and deeper tissues as well as fatigue. Possibly the princess in Hans Christian Andersen's ‘The Princess and the Pea’ suffered from FMS since chronic sleep disturbances are typical in FMS. These sleep disturbances have been attributed to a dysfunction in the systems regulating sleep and wakefulness resulting in loss of deep sleep. In addition, many patients with FMS experience cognitive dysfunction, characterised by impaired concentration and short term memory consolidation, a complaint also commonly reported in other sleep disorders. In recent reviews evaluating the efficacy of acupuncture in FMS it has been concluded that acupuncture has no specific effect. A prerequisite for this conclusion is that all the major symptoms in the syndrome have been assessed. However, previous studies have generally focused on the pain alleviating effect of acupuncture in FMS. We have observed that not only pain but also sleep and cognitive dysfunction may be ameliorated in response to acupuncture, suggesting that these variables should be taken into account when evaluating the effects of acupuncture in FMS. Furthermore, the results demonstrated great individual variability apart from the systematic effects related to the group, indicating that individually performed treatment strategies are required. Our suggestion is supported by experimental and clinical studies showing that acupuncture may affect in somnia and alertness, and that there may be neurophysiologic bases for these specific effects.

scholarly journals A contemporary view of the possibilities of preventing dementia

2019 ◽  
pp. 52-58
Author(s):  
A. N. Bogolepova
Keyword(s):  
Physical Activity ◽  
Risk Factors ◽  
Cognitive Impairment ◽  
Primary Prevention ◽  
Sleep Disturbances ◽  
Healthy Lifestyle ◽  
Neuroprotective Effect ◽  
Experimental Studies ◽  
Slowing Down ◽  
Drug Treatments

The prevalence of dementia increases progressively, which actualizes the issue of prevention. Primary prevention of dementia involves preventing the transformation of mild cognitive impairment (MCI) into dementia, secondary prevention involves the early detection and early treatment of dementia, and tertiary prevention involves slowing down the progression of dementia. Current studies pay much attention to the correction of modifiable risk factors due to lifestyle, as primary prevention. Physical activity is a very important component of a healthy lifestyle, which is aimed at preventing the development of cognitive decline. The mechanisms of the positive effect of physical activity on cognitive functions are associated with decreased risk of cardiovascular disease, increased cerebral perfusion and cerebral blood flow, changes in neurogenesis and neuronal plasticity. Nutrition strategies focus on dieting, among which the Mediterranean diet has produced hopeful results. Sleep normalization is also considered a very important aspect of the prevention of cognitive impairment, because sleep disturbances provoke the development of cardiovascular pathology and affect the amyloid metabolism. However, along with combating risk factors, more and more attention is now being paid to the possibilities of drug treatments to prevent dementia. The experimental studies confirmed the neuroprotective effect of Akatinol (memantine). The clinical studies proved the efficacy of Akatinol in the treatment of Alzheimer’s disease and vascular dementia and showed the disease-modifying effect.

scholarly journals Chronic gastroduodenal pathology in schoolchildren: the clinical picture and features of the course

2021 ◽  
Vol 1 (1) ◽  
pp. 111-117
Author(s):  
Sh. T. Turdieva ◽  
D. K. Ganieva ◽  
Kh. B. Abdurashidova
Keyword(s):  
Helicobacter Pylori ◽  
Sleep Disturbances ◽  
Clinical Symptoms ◽  
Clinical Manifestations ◽  
Pain Syndrome ◽  
Blood Analysis ◽  
Immunochromatographic Test ◽  
Respiratory Test ◽  
Loss Of Appetite ◽  
Ph Metry

The aim of the study was to study the course and clinical manifestations of chronic gastroduodenal pathology (CGDP) in schoolchildren.Materials and methods. Clinically examined 286 children and adolescents from 6 to 15 years old with СGDP. The research methods included collection of anamnestic data, instrumental and functional (esophagogastroduodenoscopy, pH-metry), clinical and laboratory (general blood analysis, coprology), and Helicobacter pylori infection was tested by respiratory test and fecal immunochromatographic test.Result. Studies have shown that the main clinical manifestations of СGDP in children were dyspeptic syndrome, vegetovascular dysfunction, and pain syndrome, against the background of objectively visible signs of anemia. Symptoms were more characteristic in patients with СGDP from vegetovascular dysfunction: loss of appetite (83.6%), fatigue (83.2%), recurrent headaches (62.2%), and sleep disturbances (59.1%). Among dyspeptic disorders, unstable stools (85%), periodic nausea (57.7%), belching (56.6%), and a feeling of heaviness in the epigastric region after eating (56.3%) prevailed. Clinical symptoms more pronounced in children with chronic gastritis.Conclusion. For schoolchildren with CGDP, vegetovascular dysfunction (98.9%) with severe dyspeptic disorders (100%) and pain (79%), against the background of objective signs of anemia (53%), is more characteristic. In adolescents is more often a less symptomatic.

scholarly journals Influence of a new derivative of 4-aminobutanoic acid on the level of neuromediatory aminoacids, neuromediators and the state of the rats’ hypocamp in conditions of brain ischemia

2021 ◽  
pp. 64-71
Author(s):  
Oksana Mishchenko ◽  
Natalia Palagina ◽  
Yuliia Larianovskaya ◽  
Tatyana Gorbach ◽  
Viktor Khomenko ◽  
...  
Keyword(s):  
Amino Acids ◽  
Hippocampal Neurons ◽  
Neuroprotective Effect ◽  
Relative Proportion ◽  
Statistical Processing ◽  
Sodium Thiopental ◽  
Neurotransmitter Amino Acids ◽  
Significance Level ◽  
Brain Neurotransmitter ◽  
The Brain

The aim: to investigate the effect of a new derivative of 4-aminobutanoic acid (compounds KGM-5) on the level of neurotransmitters and neurotransmitter amino acids and the structural-functional state of the hippocampus of rats with acute cerebrovascular accident (ACVA). Materials and methods. ACVA was reproduced in rats by occlusion of the left carotid artery under anesthesia (sodium thiopental (35 mg/kg) intraperitoneally (i/p). 5 groups of animals were used: intact control (IC, n=6), untreated animals with ACVA (CP, n=13); animals with ACVA (n=14), which were treated for 5 days with KGM-5 at a dose of 30 mg/kg i/p, animals with ACVA (n=13), who received i/p comparison drug “Picamilon” (17 mg/kg). There was a group of pseudo-operated animals (POA, n=8). Withdrawal of animals from the experiment was performed on day 6 after modeling ACVA by painless euthanasia under anesthesia. Histological examinations of CA1 and CA3 zones of the ventral hippocampus were performed with staining of sections with thionine by the method of Nissl and hematoxylin, eosin. In the rat brain, neurotransmitter amino acids and neurotransmitters were identified. Statistical processing was performed using the W-Shapiro-Wills test to verify the normality of the distribution and the nonparametric Mann-Whitney U-test. The accepted significance level is p<0.05. Results. Under the influence of the compound KGM-5 and “Picamilon” in the CA1 zone of the hippocampus, the number of normochromic neurons increased by 20 % and 16.6 %, respectively, hyperchromic pycnomorphic neurons and shadow cells decreased respectively by 5.8; 2.9 times and 6.3; 3.5 times, the index of alteration of neurons decreased by 6 times and 4.8 times, respectively, the area of ​​the perikaryon of these neurons increased by 39.7 % and 77.8 %, respectively, compared with KP (p<0.05). Both studied agents showed a less pronounced normalizing effect on the CA3 area of the hippocampus. The new compound KGM-5 showed a normalizing effect similar to “Picamilon” on the level of neurotransmitter amino acids and neurotransmitters in the brain of rats with ACVA. Conclusions. Therapeutic administration of KGM-5 increases the survival of ventral hippocampal neurons, reducing the relative proportion of irreversibly altered cells, and helps to restore impaired levels of neurotransmitter amino acids and neurotransmitters in the brain of rats with ACVA. The neuroprotective effect of the new compound KGM-5 corresponds to this comparison drug “Picamilon”

scholarly journals Effectiveness of laser therapy for the treatment of lumbosacral radiculoischemias

2021 ◽  
Vol 20 (1) ◽  
pp. 50-61
Author(s):  
V. V. Andreev ◽  
S. V. Zevakhin ◽  
E. R. Barantsevich ◽  
A. I. Sychov ◽  
N. N. Petrishev
Keyword(s):  
Laser Therapy ◽  
Neuroprotective Effect ◽  
Clinical Manifestations ◽  
Pain Syndrome ◽  
Clinical Effectiveness ◽  
Intervertebral Discs ◽  
Neurological Manifestations ◽  
Low Intensity ◽  
Spinal Roots ◽  
Laser Disk

Introduction.The study was devoted to assessing the effectiveness of laser therapy in the treatment of spondylogenic radiculoischemias. Low-intensity laser therapy and vaporization technology were used.Aim – to improve treatment and outcomes in patients with compression of the spinal roots in herniated intervertebral discs using various methods of laser therapy.Materials and methods. In two groups, the results of treatment of 225 patients with clinical manifestations of spondylogenic lumbosacral radiculoischemias were analyzed using laser therapy techniques. In 115 cases (group 1), laser treatment was performed using the method of puncture polychannel laser disk decompression. In 110 patients (group 2), low-intensity percutaneous laser therapy was used. The dynamics of the clinical and neurological manifestations of the disease was recorded: the time of pain syndrome reduction, the dynamics of motor and sensory disorders of the corresponding root, changes in parameters according to the Roland-Morris and Oswestry Disability questionnaire.Results. In both groups, an improvement in clinical and neurological manifestations was obtained: the intensity of pain syndrome according to VAS decreased in more than 70 % of the observed individuals. A significant improvement in the parameters of vital activity was revealed according to scales with a long-lasting effect (more than 12 months) with an improvement in the blood supply to the spinal roots.Conclusion. Laser radiation has significant clinical effectiveness; the important parameters are the wavelength and rate of the radiation. Structural-modifying action and improvement of microcirculation (of arterial and venous bed) are achieved. Evaluation of the effectiveness of polychannel laser puncture decompression is advisable using scales and questionnaires. Low-intensity percutaneous laser therapy and monochannel interstitial laser therapy provide a targeted antiedemic and neuroprotective effect with the possibility of dosing and control. The treatment is highly effective and improves the prognosis of the disease.

Sign in / Sign up

Export Citation Format

Share Document